Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the safety and efficacy of ARI0002h, a novel academic BCMA-directed CAR-T therapy, for the treatment of patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.